Predictions
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€13.26
09.01.22
09.01.22
-
09.01.23
09.01.23
7.05%
10.01.23
10.01.23
Risky Investment
Precision BioSciences Inc
Start price
Target price
Perf. (%)
€5.87
09.01.22
09.01.22
-
09.01.23
09.01.23
-79.37%
10.01.23
10.01.23
Probably not worthwhile Investment
MorphoSys AG
Start price
Target price
Perf. (%)
€30.80
08.01.22
08.01.22
-
08.01.26
08.01.26
-46.20%
05.09.22
05.09.22
Probably not worthwhile Investment
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
120.38%
22:26
22:26
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Magenta Therapeutics
Start price
Target price
Perf. (%)
€4.08
08.01.22
08.01.22
€6.00
08.01.23
08.01.23
-26.40%
22.01.22
22.01.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Novavax Inc.
Start price
Target price
Perf. (%)
€114.10
07.01.22
07.01.22
€130.00
07.01.23
07.01.23
-63.63%
05.06.22
05.06.22
Could be worthwhile Investment >10% per year
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€19.50
06.01.22
06.01.22
-
06.01.23
06.01.23
-45.13%
13.03.22
13.03.22
Riot Blockchain Inc.
Start price
Target price
Perf. (%)
€18.94
05.01.22
05.01.22
-
05.01.23
05.01.23
-7.08%
09.01.22
09.01.22
Risky Investment
Valneva SE
Start price
Target price
Perf. (%)
€19.03
04.01.22
04.01.22
-
04.01.23
04.01.23
-7.46%
07.01.22
07.01.22
Risky Investment
Eckert & Ziegler Strahlen- und Medizintechnik AG
Start price
Target price
Perf. (%)
€98.65
04.01.22
04.01.22
-
04.01.23
04.01.23
-56.84%
25.08.22
25.08.22
Edap Tms S.A. ADR
Start price
Target price
Perf. (%)
€5.00
03.01.22
03.01.22
-
03.01.23
03.01.23
27.00%
15.05.22
15.05.22
Probably not worthwhile Investment
Pfizer Inc.
Start price
Target price
Perf. (%)
€50.01
03.01.22
03.01.22
€78.00
03.01.23
03.01.23
-2.98%
04.01.23
04.01.23
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Undervalued
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€3.54
03.01.22
03.01.22
-
03.01.23
03.01.23
-14.69%
09.01.22
09.01.22
Risky Investment
Axsome Therapeutics Inc
Start price
Target price
Perf. (%)
€33.72
03.01.22
03.01.22
-
03.01.23
03.01.23
-14.00%
09.01.22
09.01.22
Risky Investment
Quantum Genomics S.A.
Start price
Target price
Perf. (%)
€4.32
31.12.21
31.12.21
€5.00
31.12.22
31.12.22
-97.78%
01.01.23
01.01.23
Could be worthwhile Investment >10% per year
Novavax Inc.
Start price
Target price
Perf. (%)
€134.44
30.12.21
30.12.21
-
30.12.22
30.12.22
-13.81%
09.01.22
09.01.22
Risky Investment
Oramed Pharmaceuticals
Start price
Target price
Perf. (%)
€11.38
29.12.21
29.12.21
€15.00
29.12.22
29.12.22
-0.92%
30.12.22
30.12.22
Could be worthwhile Investment >10% per year
Oramed Pharmaceuticals
Start price
Target price
Perf. (%)
€10.70
29.12.21
29.12.21
-
29.12.22
29.12.22
5.37%
30.12.22
30.12.22
Risky Investment
Mainly gamblers invest here
Sustainability is not important
High valuation
BiondVax Pharmaceuticals Ltd ADR
Start price
Target price
Perf. (%)
€22.60
28.12.21
28.12.21
-
28.12.22
28.12.22
-32.74%
07.01.22
07.01.22
Probably not worthwhile Investment
Tandem Diabetes Care Inc
Start price
Target price
Perf. (%)
€136.00
28.12.21
28.12.21
€142.00
28.12.22
28.12.22
-70.42%
29.12.22
29.12.22
Could be worthwhile Investment >10% per year
Capable Management
Future proof or reliable business model
Opko Health Inc.
Start price
Target price
Perf. (%)
€4.65
28.12.21
28.12.21
-
28.12.22
28.12.22
-75.54%
29.12.22
29.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Johnson & Johnson
Start price
Target price
Perf. (%)
€149.96
28.12.21
28.12.21
-
28.12.22
28.12.22
10.44%
29.12.22
29.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Good culture
Top 10 in its market